| MeSH term | MeSH ID | Detail |
|---|---|---|
| Stomach Ulcer | D013276 | 75 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
| Pain | D010146 | 64 associated lipids |
| Inflammation | D007249 | 119 associated lipids |
| Reperfusion Injury | D015427 | 65 associated lipids |
| Colitis | D003092 | 69 associated lipids |
| Diabetes Mellitus, Experimental | D003921 | 85 associated lipids |
| Body Weight | D001835 | 333 associated lipids |
| Arthritis, Experimental | D001169 | 24 associated lipids |
| Hypotension | D007022 | 41 associated lipids |
2-arachidonoylglycerol
2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
Cross Reference
Introduction
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2-arachidonoylglycerol?
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
PubChem Associated disorders and diseases
What pathways are associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2-arachidonoylglycerol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2-arachidonoylglycerol?
Knock-out
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with 2-arachidonoylglycerol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| van der Stelt M et al. | A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. | 2005 | FASEB J. | pmid:15894565 |
| Lambert DM and Fowler CJ | The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. | 2005 | J. Med. Chem. | pmid:16078824 |
| Hayase T et al. | Persistent anxiogenic effects of a single or repeated doses of cocaine and methamphetamine: interactions with endogenous cannabinoid receptor ligands. | 2005 | Behav Pharmacol | pmid:16148444 |
| Venderova K et al. | Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. | 2005 | Exp. Neurol. | pmid:15899265 |
| Sancho R et al. | Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. | 2005 | J. Immunol. | pmid:16148147 |
| Kishimoto S et al. | Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. | 2005 | J. Biochem. | pmid:15749836 |
| Julien B et al. | Antifibrogenic role of the cannabinoid receptor CB2 in the liver. | 2005 | Gastroenterology | pmid:15765409 |
| Kaplan BL et al. | 2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. | 2005 | J. Leukoc. Biol. | pmid:15774549 |
| Lauckner JE et al. | The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. | 2005 | Proc. Natl. Acad. Sci. U.S.A. | pmid:16365309 |
| Chen J et al. | Finding of endocannabinoids in human eye tissues: implications for glaucoma. | 2005 | Biochem. Biophys. Res. Commun. | pmid:15823551 |
| Hill MN et al. | Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. | 2005 | Eur. J. Pharmacol. | pmid:16324692 |
| Gokoh M et al. | 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, enhances the adhesion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes. | 2005 | FEBS Lett. | pmid:16288744 |
| Iturralde M et al. | Characterization of the lipolytic pathways that mediate free fatty acid release during Fas/CD95-induced apoptosis. | 2005 | Apoptosis | pmid:16215685 |
| Safo PK and Regehr WG | Endocannabinoids control the induction of cerebellar LTD. | 2005 | Neuron | pmid:16301180 |
| Alger BE | Endocannabinoid identification in the brain: studies of breakdown lead to breakthrough, and there may be NO hope. | 2005 | Sci. STKE | pmid:16278487 |
| Maccarrone M et al. | Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility. | 2005 | Mol. Hum. Reprod. | pmid:15563449 |
| Rademacher DJ et al. | Waterborne lead exposure affects brain endocannabinoid content in male but not female fathead minnows (Pimephales promelas). | 2005 | Neurotoxicology | pmid:15527869 |
| Shoemaker JL et al. | Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. | 2005 | J. Pharmacol. Exp. Ther. | pmid:16081674 |
| Sipe JC et al. | Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. | 2005 | J. Leukoc. Biol. | pmid:15845647 |
| Jung KM et al. | Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors. | 2005 | Mol. Pharmacol. | pmid:16051747 |
| Makara JK et al. | Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. | 2005 | Nat. Neurosci. | pmid:16116451 |
| Ligresti A et al. | Endocannabinoid metabolic pathways and enzymes. | 2005 | Curr Drug Targets CNS Neurol Disord | pmid:16375679 |
| Secko D | Analgesia through endogenous cannabinoids. | 2005 | CMAJ | pmid:16103504 |
| Maejima T et al. | Synaptically driven endocannabinoid release requires Ca2+-assisted metabotropic glutamate receptor subtype 1 to phospholipase Cbeta4 signaling cascade in the cerebellum. | 2005 | J. Neurosci. | pmid:16033892 |
| Panikashvili D et al. | CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. | 2005 | J. Cereb. Blood Flow Metab. | pmid:15729296 |
| Shoemaker JL et al. | The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. | 2005 | J. Pharmacol. Exp. Ther. | pmid:15901805 |
| Saario SM et al. | Characterization of the sulfhydryl-sensitive site in the enzyme responsible for hydrolysis of 2-arachidonoyl-glycerol in rat cerebellar membranes. | 2005 | Chem. Biol. | pmid:15975510 |
| Gabbay E et al. | Endocannabinoids and liver disease--review. | 2005 | Liver Int. | pmid:16162147 |
| Vandevoorde S et al. | Influence of the degree of unsaturation of the acyl side chain upon the interaction of analogues of 1-arachidonoylglycerol with monoacylglycerol lipase and fatty acid amide hydrolase. | 2005 | Biochem. Biophys. Res. Commun. | pmid:16181610 |
| Cabranes A et al. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. | 2005 | Neurobiol. Dis. | pmid:16242629 |
| Ramos JA et al. | Therapeutic potential of the endocannabinoid system in the brain. | 2005 | Mini Rev Med Chem | pmid:16026307 |
| Wagner JA et al. | Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. | 2005 | J. Cardiovasc. Pharmacol. | pmid:16116341 |
| McPartland JM et al. | Cannabimimetic effects of osteopathic manipulative treatment. | 2005 | J Am Osteopath Assoc | pmid:16118355 |
| Wahn H et al. | The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. | 2005 | Am. J. Physiol. Heart Circ. Physiol. | pmid:16055511 |
| Kurabayashi M et al. | 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. | 2005 Jan-Feb | J Invest Surg | pmid:15804949 |
| Mechoulam R et al. | Endocannabinoids, feeding and suckling--from our perspective. | 2006 | Int J Obes (Lond) | pmid:16570101 |
| Matias I et al. | Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. | 2006 | Int J Obes (Lond) | pmid:16570107 |
| Bari M et al. | New insights into endocannabinoid degradation and its therapeutic potential. | 2006 | Mini Rev Med Chem | pmid:16515464 |
| Matias I et al. | Changes in endocannabinoid and palmitoylethanolamide levels in eye tissues of patients with diabetic retinopathy and age-related macular degeneration. | 2006 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:17011761 |
| Spoto B et al. | Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. | 2006 | Biochimie | pmid:16949718 |
| Quistad GB et al. | Monoacylglycerol lipase inhibition by organophosphorus compounds leads to elevation of brain 2-arachidonoylglycerol and the associated hypomotility in mice. | 2006 | Toxicol. Appl. Pharmacol. | pmid:16310817 |
| van der Stelt M et al. | Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. | 2006 | Cell. Mol. Life Sci. | pmid:16732431 |
| Panikashvili D et al. | The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. | 2006 | Neurobiol. Dis. | pmid:16364651 |
| Saario SM et al. | URB754 has no effect on the hydrolysis or signaling capacity of 2-AG in the rat brain. | 2006 | Chem. Biol. | pmid:16931330 |
| Sang N et al. | PGE2 glycerol ester, a COX-2 oxidative metabolite of 2-arachidonoyl glycerol, modulates inhibitory synaptic transmission in mouse hippocampal neurons. | 2006 | J. Physiol. (Lond.) | pmid:16484297 |
| Parkkari T et al. | Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability. | 2006 | Bioorg. Med. Chem. Lett. | pmid:16466915 |
| Kurihara R et al. | Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. | 2006 | J. Biol. Chem. | pmid:16513651 |
| Mestre L et al. | The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. | 2006 | Biochem. Pharmacol. | pmid:16914119 |
| McCarron RM et al. | Endothelial-mediated regulation of cerebral microcirculation. | 2006 | J. Physiol. Pharmacol. | pmid:17244945 |
| Parrish JC and Nichols DE | Serotonin 5-HT(2A) receptor activation induces 2-arachidonoylglycerol release through a phospholipase c-dependent mechanism. | 2006 | J. Neurochem. | pmid:17010161 |